EAST NORRITON, Pa., Oct. 26 /PRNewswire-FirstCall/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, November 1, 2010 at 5:00 p.m. EDT to provide a business update and discuss its third quarter 2010 financial results.
To participate in the call, please dial 888.713.4213 (domestic) or 617.213.4865 (international) and reference the access code 30673244.
This conference call will also be webcast live under the Investors section of the Company's website at http://www.tengion.com and archived until December 1, 2010.
Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. A Phase I clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.